


**Epidemiologic/Correlative**

- UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)
- UCI 16-01** Pathway Analysis for Individualized Network Therapeutic for Cancer (PAINT) (Nelson)
- UCI 16-43** Prospective Collection of Human Colon Cancer Tissue Samples for Development of Patient Derived Xenograft Mouse Models and 3D-Vascularized Microtumor Chambers (Lyou)
- UCI 17-76\*\*** Variations in Local Microbiome Populations in Normal Colorectal Tissue and Polyps (Whiteson)

**Therapeutic - Multi-site  
(including colon)**

- UCI 15-74** Phase II Entrectinib Tx Patients with Locally Advanced/Metastatic Solid Tumors Harbor NTRK1/2/3, ROS1, ALK Gene (Seery)
- UCI 16-96** Phase I Study of the Highly-Selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)
- UCI 17-50\*\*** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate in Subjects with Advanced Solid Tumor (Ou)



**Screening**

- UCI 12-40** Atlas Colorectal Health Network (Park)
- UCI 14-30** Low Residue Diet vs. Clear Liquid Diet w/ Split dose PEG-ELS for Colon Cleansing Prior to Colonoscopy (Samarasena)

**Stage IIA/IIIA  
(T2N1,T3N0,T3N1)**

**Neoadjuvant**

**SWOG N1048** Phase II/III Trial of Neoadjuvant FOLFOX w/ Selective Use of Combined Modality Chemoradiation VS Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal CA Pts Undergoing LAR W/Total Mesorectal Excision (Pigazzi)

**Post-Adjuvant**

**Stage 0-III**

**SWOG S0820** Phase IIA Randomized Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High-Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer (Zell)

**COLORECTAL  
CANCER**

**Perioperative**

**UCI 17-28\*\*** Immediate Adjuvant Chemotherapy for Invasive Colonic Adenocarcinoma (Pigazzi)

**Stage IV**

**1<sup>st</sup> Line**

**UCI 15-96** A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (Zell)

**2<sup>nd</sup> Line**

**ECOG-EAY131** Molecular Analysis for Therapy Choice (MATCH) (Seery)